Your browser doesn't support javascript.
loading
PROFICS: A bacterial selection system for directed evolution of proteases.
Kröß, Christina; Engele, Petra; Sprenger, Bernhard; Fischer, Andreas; Lingg, Nico; Baier, Magdalena; Öhlknecht, Christoph; Lier, Bettina; Oostenbrink, Chris; Cserjan-Puschmann, Monika; Striedner, Gerald; Jungbauer, Alois; Schneider, Rainer.
Afiliação
  • Kröß C; acib GmbH, Graz, Austria; Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
  • Engele P; acib GmbH, Graz, Austria; Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
  • Sprenger B; acib GmbH, Graz, Austria; Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
  • Fischer A; acib GmbH, Graz, Austria; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Lingg N; acib GmbH, Graz, Austria; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Baier M; Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
  • Öhlknecht C; acib GmbH, Graz, Austria; Institute of Molecular Modeling and Simulation, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Lier B; acib GmbH, Graz, Austria; Institute of Molecular Modeling and Simulation, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Oostenbrink C; acib GmbH, Graz, Austria; Institute of Molecular Modeling and Simulation, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Cserjan-Puschmann M; acib GmbH, Graz, Austria; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Striedner G; acib GmbH, Graz, Austria; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Jungbauer A; acib GmbH, Graz, Austria; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Schneider R; acib GmbH, Graz, Austria; Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria. Electronic address: rainer.schneider@uibk.ac.at.
J Biol Chem ; 297(4): 101095, 2021 10.
Article em En | MEDLINE | ID: mdl-34418435
Proteases serve as important tools in biotechnology and as valuable drugs or drug targets. Efficient protein engineering methods to study and modulate protease properties are thus of great interest for a plethora of applications. We established PROFICS (PRotease Optimization via Fusion-Inhibited Carbamoyltransferase-based Selection), a bacterial selection system, which enables the optimization of proteases for biotechnology, therapeutics or diagnosis in a simple overnight process. During the PROFICS process, proteases are selected for their ability to specifically cut a tag from a reporter enzyme and leave a native N-terminus. Precise and efficient cleavage after the recognition sequence reverses the phenotype of an Escherichia coli knockout strain deficient in an essential enzyme of pyrimidine synthesis. A toolbox was generated to select for proteases with different preferences for P1' residues (the residue immediately following the cleavage site). The functionality of PROFICS is demonstrated with viral proteases and human caspase-2. PROFICS improved caspase-2 activity up to 25-fold after only one round of mutation and selection. Additionally, we found a significantly improved tolerance for all P1' residues caused by a mutation in a substrate interaction site. We showed that this improved activity enables cells containing the new variant to outgrow cells containing all other mutants, facilitating its straightforward selection. Apart from optimizing enzymatic activity and P1' tolerance, PROFICS can be used to reprogram specificities, erase off-target activity, optimize expression via tags/codon usage, or even to screen for potential drug-resistance-conferring mutations in therapeutic targets such as viral proteases in an unbiased manner.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cisteína Endopeptidases / Engenharia de Proteínas / Evolução Molecular Direcionada / Escherichia coli / Caspase 2 Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Áustria País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cisteína Endopeptidases / Engenharia de Proteínas / Evolução Molecular Direcionada / Escherichia coli / Caspase 2 Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Áustria País de publicação: Estados Unidos